{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:12:51Z","timestamp":1791357171740,"version":"4.3.1"},"reference-count":33,"publisher":"American Psychiatric Association Publishing","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AJP"],"published-print":{"date-parts":[[2003,8,1]]},"DOI":"10.1176\/appi.ajp.160.8.1421","type":"journal-article","created":{"date-parts":[[2003,8,4]],"date-time":"2003-08-04T17:35:14Z","timestamp":1060018514000},"page":"1421-1427","source":"Crossref","is-referenced-by-count":78,"title":["The Relationship of Clozapine and Haloperidol Treatment Response to Prefrontal, Hippocampal, and Caudate Brain Volumes"],"prefix":"10.1176","volume":"160","author":[{"given":"Celso","family":"Arango","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Breier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"William T.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"230","reference":[{"key":"R1608BEJDDHDG","doi-asserted-by":"crossref","unstructured":"Buchanan RW: Clozapine: efficacy and safety. Schizophr Bull 1995; 21:579\u2013591","DOI":"10.1093\/schbul\/21.4.579"},{"key":"R1608BEJJHCIG","doi-asserted-by":"crossref","unstructured":"Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G: Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49:538\u2013544","DOI":"10.1001\/archpsyc.1992.01820070032005"},{"key":"R1608BEJGFJHG","doi-asserted-by":"crossref","unstructured":"Friedman L, Knutson L, Shurell M, Meltzer HY: Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia. Biol Psychiatry 1991; 29:865\u2013877","DOI":"10.1016\/0006-3223(91)90053-O"},{"key":"R1608BEJGCBEB","doi-asserted-by":"crossref","unstructured":"Honer WG, Smith GN, Lapointe JS, MacEwan GW, Kopala L, Altman S: Regional cortical anatomy and clozapine response in refractory schizophrenia. Neuropsychopharmacology 1995; 13:85\u201387","DOI":"10.1038\/sj.npp.1380276"},{"key":"R1608BEJFBGDJ","unstructured":"Bilder RM, Wu H, Chakos MH, Bogerts B, Pollack S, Aronowitz J, Ashtari M, Degreef G, Kane JM, Lieberman JA: Cerebral morphometry and clozapine treatment in schizophrenia. J Clin Psychiatry 1994; 55(suppl B):53\u201356"},{"key":"R1608BEJFHAHG","doi-asserted-by":"crossref","unstructured":"Lauriello J, Mathalon DH, Rosenbloom M, Sullivan EV, Faustman WO, Ringo DL, Lim KO, Pfefferbaum A: Association between regional brain volumes and clozapine response in schizophrenia. Biol Psychiatry 1998; 43:879\u2013886","DOI":"10.1016\/S0006-3223(97)00491-5"},{"key":"R1608BEJFDBCE","doi-asserted-by":"crossref","unstructured":"Molina Rodr\u00edguez V, Montz Andre\u00e9 R, P\u00e9rez Castej\u00f3n MJ, Capdevila Garc\u00eda E, Carreras Delgado JL, Rubia Vila FJ: SPECT study of regional cerebral perfusion in neuroleptic-resistant schizophrenic patients who responded or did not respond to clozapine. Am J Psychiatry 1996; 153:1343\u20131346","DOI":"10.1176\/ajp.153.10.1343"},{"key":"R1608BEJCIAHE","doi-asserted-by":"crossref","unstructured":"Molina Rodr\u00edguez V, Montz Andre\u00e9 R, P\u00e9rez Castej\u00f3n MJ, Zamora ML, Alvaro PC, Carreras Delgado JL, Rubia Vila FJ: Fronto-striato-thalamic perfusion and clozapine response in treatment-refractory schizophrenic patients: a 99mTc-HMPAO study. Psychiatry Res 1997; 76:51\u201361","DOI":"10.1016\/S0925-4927(97)00057-7"},{"key":"R1608BEJEBJGG","doi-asserted-by":"crossref","unstructured":"Buchanan RW, Carpenter WT Jr: The neuroanatomies of schizophrenia. Schizophr Bull 1997; 23:367\u2013372","DOI":"10.1093\/schbul\/23.3.367"},{"key":"R1608BEJHCACD","doi-asserted-by":"crossref","unstructured":"Carpenter WT Jr, Buchanan RW, Kirkpatrick B, Tamminga C, Wood F: Strong inference, theory testing, and the neuroanatomy of schizophrenia. Arch Gen Psychiatry 1993; 50:825\u2013831","DOI":"10.1001\/archpsyc.1993.01820220081009"},{"key":"R1608BEJBJDHD","doi-asserted-by":"crossref","unstructured":"Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT Jr: Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151:20\u201326","DOI":"10.1176\/ajp.151.1.20"},{"key":"R1608BEJGFBEB","doi-asserted-by":"crossref","unstructured":"Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr: Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 1998; 155:751\u2013760","DOI":"10.1176\/ajp.155.6.751"},{"key":"R1608BEJFBEBH","doi-asserted-by":"crossref","unstructured":"Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799\u2013812","DOI":"10.2466\/pr0.1962.10.3.799"},{"key":"R1608BEJEFFDJ","doi-asserted-by":"crossref","unstructured":"Andreasen NC: The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry Suppl 1989; 7:49\u201358","DOI":"10.1192\/S0007125000291496"},{"key":"R1608BEJICCHJ","doi-asserted-by":"crossref","unstructured":"Buchanan RW, Carpenter WT: Domains of psychopathology: an approach to the reduction of heterogeneity in schizophrenia. J Nerv Ment Dis 1994; 182:193\u2013204","DOI":"10.1097\/00005053-199404000-00001"},{"key":"R1608BEJHCDDF","doi-asserted-by":"crossref","unstructured":"Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11\u201319","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"R1608BEJJCAFG","doi-asserted-by":"crossref","unstructured":"Breier A, Buchanan RW, Elkashef A, Munson RC, Kirkpatrick B, Gellad F: Brain morphology and schizophrenia: a magnetic resonance imaging study of limbic, prefrontal cortex, and caudate structures. Arch Gen Psychiatry 1992; 49:921\u2013926","DOI":"10.1001\/archpsyc.1992.01820120009003"},{"key":"R1608BEJJFGAJ","doi-asserted-by":"crossref","unstructured":"Buchanan RW, Breier A, Kirkpatrick B, Elkashef A, Munson RC, Gellad F, Carpenter WT Jr: Structural abnormalities in deficit and nondeficit schizophrenia. Am J Psychiatry 1993; 150:59\u201365","DOI":"10.1176\/ajp.150.1.59"},{"key":"R1608BEJBCCAA","doi-asserted-by":"crossref","unstructured":"Schad LR, Brix G, Zuna I, Harle W, Lorenz WJ, Semmler W: Multiexponential proton spin-spin relaxation in MR imaging of human brain tumors. J Comput Assist Tomogr 1989; 13:577\u2013587","DOI":"10.1097\/00004728-198907000-00005"},{"key":"R1608BEJHAIJA","doi-asserted-by":"crossref","unstructured":"Wolkin A, Sanfilipo M, Wolf AP, Angrist B, Brodie JD, Rotrosen J: Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiatry 1992; 49:959\u2013965","DOI":"10.1001\/archpsyc.1992.01820120047007"},{"key":"R1608BEJFIHII","doi-asserted-by":"crossref","unstructured":"Scheepers FE, de Wied CC, Hulshoff Pol HE, van de Flier W, van der Linden JA, Kahn RS: The effect of clozapine on caudate nucleus volume in schizophrenic patients previously treated with typical antipsychotics. Neuropsychopharmacology 2001; 24:47\u201354","DOI":"10.1016\/S0893-133X(00)00172-X"},{"key":"R1608BEJDBICG","doi-asserted-by":"crossref","unstructured":"Scheepers FE, Gispen de Wied CC, Hulshoff Pol HE, Kahn RS: Effect of clozapine on caudate nucleus volume in relation to symptoms of schizophrenia. Am J Psychiatry 2001; 158:644\u2013646","DOI":"10.1176\/appi.ajp.158.4.644"},{"key":"R1608BEJFJFGJ","doi-asserted-by":"crossref","unstructured":"Kane JM, Marder SR, Schooler NR, Wirshing WC, Umbricht D, Baker RW, Wirshing DA, Safferman A, Ganguli R, McMeniman M, Borenstein M: Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry 2001; 58:965\u2013972","DOI":"10.1001\/archpsyc.58.10.965"},{"key":"R1608BEJEEDDA","doi-asserted-by":"crossref","unstructured":"Rosenheck R, Dunn L, Peszke M, Cramer J, Xu W, Thomas J, Charney D (Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia): Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Am J Psychiatry 1999; 156:88\u201393","DOI":"10.1176\/ajp.156.1.88"},{"key":"R1608BEJFJGIJ","doi-asserted-by":"crossref","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer H (Clozaril Collaborative Study Group): Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789\u2013796","DOI":"10.1001\/archpsyc.1988.01800330013001"},{"key":"R1608BEJIIJHE","doi-asserted-by":"crossref","unstructured":"Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH: Clinical and biologic response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiatry 1992; 49:345\u2013353","DOI":"10.1001\/archpsyc.1992.01820050009001"},{"key":"R1608BEJBACCE","unstructured":"Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Bookstein P, Kane JM: Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994; 151:1744\u20131752"},{"key":"R1608BEJFFABD","doi-asserted-by":"crossref","unstructured":"Rosenheck R, Charney D, Cramer J, Xu W, Thomas J (VA CSH 17 Study Group): A randomized, double-blind trial of the efficacy and cost-effectiveness of clozapine (abstract). Schizophr Res 1997; 24:188","DOI":"10.1016\/S0920-9964(97)82537-6"},{"key":"R1608BEJBADEC","doi-asserted-by":"crossref","unstructured":"Marder SR, Van Putten T, Mintz J, McKenzie J, Lebell M, Faltico G, May PRA: Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry 1984; 41:1025\u20131029","DOI":"10.1001\/archpsyc.1983.01790220015002"},{"key":"R1608BEJGGFGA","doi-asserted-by":"crossref","unstructured":"Van Putten T, May PR, Marder SR: Akathisia with haloperidol and thiothixene. Arch Gen Psychiatry 1984; 41:1036\u20131039","DOI":"10.1001\/archpsyc.1983.01790220026004"},{"key":"R1608BEJCGDDE","doi-asserted-by":"crossref","unstructured":"Nyberg S, Nakashima Y, Nordstrom AL, Halldin C, Farde L: Positron emission tomography of in-vivo binding characteristics of atypical antipsychotic drugs: review of D2 and 5-HT2 receptor occupancy studies and clinical response. Br J Psychiatry Suppl 1996; 29:40\u201344","DOI":"10.1192\/S0007125000298309"},{"key":"R1608BEJICJDA","doi-asserted-by":"crossref","unstructured":"Kapur S, Zipursky RB, Remington G: Clinical and theoretical implications of 5-HT2and D2receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999; 156:286\u2013293","DOI":"10.1176\/ajp.156.2.286"},{"key":"R1608BEJBCDIC","doi-asserted-by":"crossref","unstructured":"Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O\u2019Laughlin IA, Meltzer HY: 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 2001; 76:1521\u20131531","DOI":"10.1046\/j.1471-4159.2001.00154.x"}],"container-title":["American Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp.160.8.1421","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T09:23:32Z","timestamp":1734081812000},"score":1,"resource":{"primary":{"URL":"https:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp.160.8.1421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,8,1]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2003,8,1]]}},"alternative-id":["10.1176\/appi.ajp.160.8.1421"],"URL":"https:\/\/doi.org\/10.1176\/appi.ajp.160.8.1421","relation":{},"ISSN":["0002-953X","1535-7228"],"issn-type":[{"value":"0002-953X","type":"print"},{"value":"1535-7228","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,8,1]]}}}